Roberts Glore & Co. Inc. IL Cuts Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Roberts Glore & Co. Inc. IL trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,548 shares of the medical equipment provider’s stock after selling 460 shares during the quarter. Roberts Glore & Co. Inc. IL’s holdings in Zimmer Biomet were worth $903,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Janney Montgomery Scott LLC raised its holdings in shares of Zimmer Biomet by 181.0% during the 3rd quarter. Janney Montgomery Scott LLC now owns 25,869 shares of the medical equipment provider’s stock valued at $2,793,000 after buying an additional 16,663 shares during the period. Graypoint LLC raised its holdings in shares of Zimmer Biomet by 6.6% during the 3rd quarter. Graypoint LLC now owns 4,829 shares of the medical equipment provider’s stock valued at $521,000 after buying an additional 299 shares during the period. Rovin Capital UT ADV raised its holdings in shares of Zimmer Biomet by 19.1% during the 3rd quarter. Rovin Capital UT ADV now owns 6,426 shares of the medical equipment provider’s stock valued at $694,000 after buying an additional 1,029 shares during the period. Atria Investments Inc raised its holdings in shares of Zimmer Biomet by 60.2% during the 3rd quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider’s stock valued at $586,000 after buying an additional 2,041 shares during the period. Finally, Mesirow Financial Investment Management Inc. raised its holdings in shares of Zimmer Biomet by 95.2% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 5,254 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 2,563 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Price Performance

Shares of ZBH opened at $107.87 on Friday. The firm has a market cap of $21.47 billion, a price-to-earnings ratio of 24.24, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $105.55 and a 200-day moving average of $107.19.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business posted $2.20 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s payout ratio is currently 21.57%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stifel Nicolaus raised their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Barclays dropped their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Truist Financial restated a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Raymond James lowered their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.